This ETF has been the tip of the arrow when it comes to trading momentum stocks.» Read More
Greg Dunn faces such challenges every day as co-manager of the $1 billion Thornburg International Growth fund, which won a 2014 U.S. Lipper Fund award for its 3- and 5- year performance in the International Multi-Cap Growth category this year from Lipper, a Thomson Reuters company.
Feb 27- Valeant Pharmaceuticals International Inc sees close to 50 opportunities for mergers or acquisitions, its chief executive said on Thursday, as it aims to become one of the world's five biggest pharmaceutical companies.
Feb 27- Valeant Pharmaceuticals International Inc, Canada's largest listed drugmaker, swung to a quarterly profit driven by the acquisition of contact lens maker Bausch& Lomb Holdings Inc.. Valeant's net income attributable to the company was $123.8 million, or 36 cents per share, for the fourth quarter ended Dec. 31.
Feb 27- Valeant Pharmaceuticals International Inc, Canada's largest listed drugmaker, reported a quarterly profit compared with a year-earlier loss, mainly driven by its acquisition of contact lens maker Bausch+ Lomb Holdings Inc..
NEW YORK, Feb 21- When big name U.S. hedge fund managers disclosed their fourth-quarter stock holdings last week, a couple of exchange-traded fund companies took particular note. Global X Funds and AlphaClone LLC both offer ETFs that mimic the stock picks of high-priced hedge funds.
NEW YORK, Feb 21- Small investors who have longed to benefit from the brains of top hedge fund managers can now purchase those same stock picks without paying hefty fees or tying up a large amount of money.
TORONTO, Feb 3- Valeant Pharmaceuticals International Inc said on Monday it has agreed to acquire privately held PreCision Dermatology Inc for $475 million in cash to strengthen its skin products business.
All good things must come to an end. Cramer says it’s time to ring the register on this stock.
Some of the names on the move ahead of the open.
Jan 7- Valeant Pharmaceuticals International Inc, Canada's largest listed drugmaker, wants to become one of the world's top five pharmaceutical companies by market capitalization by the end of 2016, largely through acquisitions, it said on Tuesday.
Jan 7- Valeant Pharmaceuticals International Inc, Canada's largest listed drugmaker, on Tuesday forecast 2014 adjusted earnings of $8.25 to $8.75 per share and revenue of $8.2 billion to $8.6 billion, both up about 40 percent from the previous year.
Dec 16- Valeant Pharmaceuticals International said on Monday that it would buy Solta Medical Inc for about $236 million in cash to add products for procedures such as skin rejuvenation, skin tightening and body contouring.
Dec 16- Valeant Pharmaceuticals International Inc, which agreed on Monday to buy Solta Medical Inc, is one of Canada's fastest-rising stocks.
Dec 16- Valeant Pharmaceuticals International said on Monday it would acquire Solta Medical Inc for about $236 million in cash, giving it access to products used in procedures such as skin rejuvenation, skin tightening and body contouring.
Oct 31- Valeant Pharmaceuticals International Inc, Canada's biggest publicly traded drugmaker, posted a quarterly net loss on Thursday after restructuring and impairment charges, and cut its full-year revenue outlook.
Oct 31- Canada's Valeant Pharmaceuticals International Inc said on Thursday that it sees small, cash-based acquisitions likely in the near term, but is also interested in a "merger of equals" involving a swap of equity.
NEW YORK, Oct 23- Aptalis Pharma Inc, a specialty drugmaker owned by private equity firm TPG Capital LP, has appointed underwriters for an initial public offering after efforts to sell the company failed, people familiar with the matter said on Wednesday.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Bullish option traders are piling into Valeant Pharmaceuticals as its shares reach all-time highs.
Neiman Marcus files registration papers for an initial public offering as its private equity owners eye an exit for their long-held investment.